Aktis Oncology (NASDAQ:AKTS) Stock Price Up 7.7% – Here’s What Happened

Aktis Oncology (NASDAQ:AKTS)’s share price rose 7.7% on Monday . The stock traded as high as $25.07 and last traded at $25.92. Approximately 344,579 shares traded hands during trading, an increase of 3% from the average session volume of 334,544 shares. The stock had previously closed at $24.07.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wedbush assumed coverage on Aktis Oncology in a report on Wednesday, August 19th. They issued an “outperform” rating and a $35.00 price target for the company. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They issued an “outperform” rating for the company. HC Wainwright raised their target price on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. Finally, Weiss Ratings raised shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $35.00.

Aktis Oncology Price Performance

The stock has a market capitalization of $1.39 billion and a price-to-earnings ratio of -31.80. The business has a fifty day moving average of $25.49 and a 200 day moving average of $21.29.

Aktis Oncology (NASDAQ:AKTS) last posted its earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million during the quarter, compared to the consensus estimate of $2.70 million. On average, equities research analysts expect that Aktis Oncology will post -1.8 EPS for the current year.

Insider Transactions at Aktis Oncology

In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of the company’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $24.56, for a total value of $119,263.36. Following the transaction, the director owned 3,506 shares of the company’s stock, valued at $86,107.36. This represents a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Institutional Investors Weigh In On Aktis Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. State of Wyoming acquired a new position in Aktis Oncology during the 2nd quarter worth $32,000. The Manufacturers Life Insurance Company raised its position in Aktis Oncology by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,044 shares of the technology company’s stock valued at $1,548,000 after purchasing an additional 1,051 shares in the last quarter. Bank of America Corp DE raised its position in Aktis Oncology by 4.2% in the 2nd quarter. Bank of America Corp DE now owns 72,835 shares of the technology company’s stock valued at $2,347,000 after purchasing an additional 2,909 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Aktis Oncology by 14.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock valued at $1,587,000 after buying an additional 6,349 shares during the period. Finally, Deutsche Bank AG boosted its stake in shares of Aktis Oncology by 49.3% in the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after buying an additional 6,942 shares during the period. 28.84% of the stock is owned by hedge funds and other institutional investors.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.